Elevance Health Inc (ELV) concluded trading on Wednesday at a closing price of $350.25, with 4.8 million shares of worth about $1.68 billion changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -5.61% during that period and on July 02, 2025 the price saw a loss of about -11.50%. Currently the company’s common shares owned by public are about 225.64M shares, out of which, 225.55M shares are available for trading.
Stock saw a price change of -6.32% in past 5 days and over the past one month there was a price change of -7.11%. Year-to-date (YTD), ELV shares are showing a performance of -35.36% which decreased to -5.06% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $357.45 but also hit the highest price of $567.26 during that period. The average intraday trading volume for Elevance Health Inc shares is 1.79 million. The stock is currently trading -7.80% below its 20-day simple moving average (SMA20), while that difference is down -10.78% for SMA50 and it goes to -15.56% lower than SMA200.
Elevance Health Inc (NYSE: ELV) currently have 225.64M outstanding shares and institutions hold larger chunk of about 92.64% of that.
The stock has a current market capitalization of $79.13B and its 3Y-monthly beta is at 0.61. PE ratio of stock for trailing 12 months is 13.67, while it has posted earnings per share of $25.63 in the same period. Its PEG reads 1.29 while making debt-to-equity ratio of 0.71. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ELV, volatility over the week remained 3.61% while standing at 2.40% over the month.
Stock’s fiscal year EPS is expected to rise by 4.36% while it is estimated to increase by 13.62% in next year. EPS is likely to grow at an annualized rate of 10.60% for next 5-years, compared to annual growth of 6.81% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Robert W. Baird on April 15, 2025 offering a Neutral rating for the stock and assigned a target price of $529 to it. Coverage by Argus stated Elevance Health Inc (ELV) stock as a Buy in their note to investors on March 17, 2025, suggesting a price target of $450 for the stock. Stock get a Neutral rating from BofA Securities on July 18, 2024.
